Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric tildrakizumab trial in moderate to severe chronic plaque psoriasis
2023-504447-14-00Phase 3Authorised
- Sponsor
- Sun Pharma
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of tildrakizumab in psoriasis (4 arms), sponsored by Sun Pharma. Primary endpoints: Pharmacokinetic parameters of tildrakizumab, PASI 75 response at Week 16 and 1 more. Planned start Jun 2024; status: authorised.
02
Drugs
tildrakizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2023-504447-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504447-14-00.